¿ÀÆÛ°Ô½ÃÆÇ |
|
|
ÀÔ·ÂÀÏÀÚ: |
2015-02-10 |
À¯È¿ÀÏÀÚ: |
104987-11-3 |
Á¦ ¸ñ:
|
Tacrolimus |
»óǰºÐ·ù: |
ÈÇкñ·á¿Í ³ó¾à |
µî·ÏºÐ·ù: |
Offer to Sell |
³» ¿ë: |
Tacrolimus
Synonyms: (2-propenyl)-,(3s-(3r*(e(1s*,3s*,4s*)),4s*,5r*,8s*,9e,12r*,14r*,15s*,16r*,18s*;,19s*,26ar*))-;16-dimethoxy-4,10,12,18-tetramethyl-8-3-(2-(4-hydroxy-3-methoxycyclohexyl)-1;19-epoxy-3h-pyrido(2,1-c)(1,4)oxaazacyclotricosine-1,7,20,21(4h,23h)-tetrone,5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5,19-dihydroxy-3-(2-(4-hydroxy-3-methoxycyclohexyl)-14,16-dim;6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5,19-dihydroxy-5;fr900506;prograf;tsukubaenolide
CAS: 104987-11-3,109581-93-3
MF: C44H69NO12
MW: 804.02
Chemical Properties White Crystalline Solid
Usage An immunosuppressant that blocks T cell proliferation in vitro by inhibiting the generation of several lymphokines, especially IL-2. Shown to inhibit the activity of FK-506 binding protein, thereby reversing its effects on sarcoplasmic reticulum Ca+2 release.
Usage FK-506 (Tacrolimus) is a macrolide immunosuppressive drug that is mainly used after allogeneic organ transplant to reduce the activity of the patient's immune system
Usage Tacrolimus (fujimycin) was discovered as a potent inhibitor of IL2 production in a targeted search for novel immunosuppressants. Tacrolimus acts by blocking T cell proliferation in vitro by inhibiting the generation of several lymphokines, notably the original target IL-2. Tacrolimus inhibits the activity of FK-506 binding protein, Ca2+-dependent phosphatase and calcineurin, and activates NF-¥êB through phosphorylation and degradation of I¥êB¥á.
Usage treatment of Cushing's syndrome |
¿¬¶ôó |
´ã
´ç ÀÚ: |
Ivy Young |
ȸ»çÁÖ¼Ò: |
No 496 Zhongshan Road, Wuhan City, Hubei Province, China 430064 |
¿ìÆí¹øÈ£: |
430064 |
ÀüȹøÈ£: |
86-027-50755963 |
ÆÑ½º¹øÈ£:
|
86-027-50755963 |
E - mail: |
ycwlb045@yccreate.com |
|